Increasing Trauma/LOQTEQ® sales in Q3/2013, empiric observations show favorable behavior of LOQTEQ®
It must be emphasized that sales in the Trauma segment increased by 53% (compared to the third quarter of 2012) and by 63% compared to last years first nine months. Trauma sales increased from EUR 1.5 million (Q3/2012) to EUR 2.3 million and from EUR 4.0 million (9m/2012) to EUR 6.5 million in the first nine months of 2013 respectively. The strong sales growth was driven mainly by sales in SMIT and BRICS countries. The first explantations of our LOQTEQ® plates show certain advantages compared to established competitive products, especially relating to the so called cold welding issue (a joining of the plate and the screw which complicate the proper removal of the implant). So far, no such complaints have been filed to aap for any LOQTEQ® product. In an ongoing in-vitro study, this empirical and highly relevant feature is to be explored further to be able to make a statistical proven and evidence-based statement.
Sales for bone cements and cementing techniques in the Biomaterials segment begin to speed up after the temporary reduction in the first half of 2013. During the fourth quarter, a full recovery is expected.
The evaluation process of the strategic options for EMCM is ongoing.
aap plans to publish the full Q3 2013 report on November 11, 2013.
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.